| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.95▼ | 2.94▼ | 2.94▼ | 3.01▼ | 3.49▼ |
| MA10 | 2.96▼ | 2.95▼ | 2.98▼ | 2.99▼ | 3.87▼ |
| MA20 | 2.95▼ | 3.00▼ | 3.03▼ | 3.53▼ | 4.06▼ |
| MA50 | 2.94▼ | 3.04▼ | 3.03▼ | 4.03▼ | 6.97▼ |
| MA100 | 2.99▼ | 3.04▼ | 3.18▼ | 4.08▼ | 7.11▼ |
| MA200 | 3.03▼ | 3.25▼ | 3.89▼ | 6.82▼ | 7.75▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.001▼ | -0.004▼ | -0.013▼ | -0.021▼ | 0.015▲ |
| RSI | 45.290▼ | 37.145▼ | 39.627▼ | 33.681▼ | 33.371▼ |
| STOCH | 22.222 | 30.620 | 12.715▼ | 49.899 | 28.320 |
| WILL %R | -100.000▼ | -77.143▼ | -81.395▼ | -83.459▼ | -88.000▼ |
| CCI | -96.724 | -41.750 | -80.668 | -37.116 | -154.222▼ |
|
Tuesday, April 07, 2026 04:56 AM
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's ...
|
|
Monday, March 30, 2026 04:47 AM
Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer’s disease Additional data submitted to the U.S. FDA with the ...
|
|
Thursday, March 26, 2026 05:18 AM
So should Anavex Life Sciences (NASDAQ:AVXL) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 10/04/26 | 3.06 | 3.075 | 2.90 | 2.94 | 849,998 |
| 09/04/26 | 3.00 | 3.12 | 2.985 | 3.05 | 787,130 |
| 08/04/26 | 3.19 | 3.23 | 3.015 | 3.04 | 999,169 |
| 07/04/26 | 2.92 | 3.105 | 2.8727 | 3.08 | 1,073,065 |
| 06/04/26 | 3.02 | 3.09 | 2.95 | 2.96 | 1,004,772 |
| 02/04/26 | 3.04 | 3.065 | 2.95 | 2.99 | 1,158,836 |
| 01/04/26 | 3.08 | 3.18 | 3.06 | 3.10 | 1,337,313 |
| 31/03/26 | 2.90 | 3.0899 | 2.90 | 3.07 | 1,863,090 |
| 30/03/26 | 2.76 | 2.85 | 2.6922 | 2.82 | 1,554,272 |
| 27/03/26 | 2.835 | 2.89 | 2.75 | 2.82 | 2,408,228 |
|
|
||||
|
|
||||
|
|